M1 Kliniken AG Publishes Half-Year Report 2026: Beauty EBIT up 23.8% to EUR 18.6 million

M1 Kliniken's H1 2026 Beauty segment revenue rose 11.0% to EUR 56.9 million and EBIT increased 23.8% to EUR 18.6 million, lifting the segment EBIT margin 330bps to 32.7%. Reported group revenue fell to EUR 76.6 million from EUR 183.5 million following the completed sale of HAEMATO Pharm, while adjusted EBIT reached EUR 19.7 million, up 9.5% year over year after excluding a EUR 4.1 million non-cash deconsolidation charge. The company is refocusing on clinic expansion and targets Beauty revenue of EUR 200-300 million by 2029 with a sustainable EBIT margin of at least 20%.

Analysis

The investable change is not the reported group growth rate but the quality of the remaining earnings base: a clinic-led model with materially higher incremental margins and less working-capital intensity than wholesale distribution. If utilization and clinician productivity are genuinely driving the margin step-up, each new clinic should contribute disproportionately to EBIT; this supports a rerating from a mixed healthcare/distribution multiple toward a consumer-health services peer set. The key diligence item is whether the improvement stems from sustainable same-clinic throughput versus temporary price/mix or unusually low central costs.

Near term, M12 may face mechanical valuation noise because headline revenue, EPS and reported EBIT obscure the continuing operation. That creates a 1-3 month opportunity if management provides clean pro-forma quarterly disclosure, including mature-clinic sales, ramp losses for newly opened sites, physician capacity utilization, and post-disposal cash proceeds. The balance-sheet deployment of disposal proceeds is a second-order catalyst: disciplined clinic rollout or buybacks would validate capital allocation, while acquisitions outside the focused model would undermine the simplification premium.

The 2029 ambition embeds a demanding clinic-expansion and demand-creation path, so investors should not capitalize the current margin at a mature premium without evidence that international units achieve German-like utilization. A consumer downturn, reimbursement/regulatory tightening around aesthetic procedures, practitioner scarcity, or discounting by local independent clinics could pressure volumes before fixed clinic costs adjust. Contrarian view: the market may underappreciate the cleaner earnings mix, but could also be overestimating how quickly a standardized aesthetic-service format travels across countries with different labor rules and consumer acquisition costs.

Key Decisions for Investors

• Initiate a small long M12 only after the next trading update confirms pro-forma Beauty revenue growth above 10% and segment EBIT margin above 30%; target a 6-12 month rerating on cleaner earnings quality, with thesis invalidated by two consecutive periods below 25% Beauty EBIT margin.
• Use any headline-led selloff caused by lower reported group revenue or EPS as an entry opportunity, but cap sizing until management discloses normalized free cash flow, net cash/debt, and the use of disposal proceeds; these are missing inputs for a full valuation recommendation.
• Monitor new-clinic ramp economics over the next 1-3 quarters: add exposure if mature-clinic productivity holds while opening costs remain contained; reduce if international expansion drives sustained margin dilution or marketing expense acceleration.
• Avoid treating the long-term revenue target as a near-term earnings catalyst. Set an alert for guidance that implies sub-10% core growth, material clinician recruitment constraints, or expansion outside core aesthetics; any of these would challenge the multiple-expansion thesis.